Scemblix outperformed standard tyrosine kinase inhibitors in treating chronic myeloid leukemia, with higher response rates and fewer side effects, according to data from the phase 3 ASC4FIRST trial. Scemblix (asciminib) further solidified its role in treating chronic myeloid leukemia (CML) […]
Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia Read More »
Identifying a biomarker to predict which patients with hepatocellular carcinoma (HCC) are most likely to respond to checkpoint inhibitor therapy is a necessary next step in the field especially as the addition of tislelizumab-jsgr (Tevimbra) to the NCCN Clinical Practice
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation Read More »
Patients with metastatic renal cell carcinoma (RCC) — a type of kidney cancer — did not experience benefits after receiving a combination of Opdivo (nivolumab) and Fotivda (tivozanib). Patients previously experienced disease progression (worsening) on or after treatment with a
Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney Cancer Read More »
